In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for patients with Wiskott-Aldrich syndrome, and OTR Therapeutics enters a strategic collaboration with Zealand to develop novel metabolic disease therapies.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, new analysis outlines what it may truly cost to fix the biopharma ecosystem, the FDA approves Waskyra for patients with Wiskott-Aldrich syndrome, and OTR Therapeutics enters a strategic collaboration with Zealand to develop novel metabolic disease therapies.
A new report examines the real cost of fixing systemic inefficiencies in the pharmaceutical industry, highlighting the growing financial strain caused by duplicative infrastructure, fragmented data ecosystems, and escalating development expenses. The analysis outlines where investment is most urgently needed to modernize operations and improve long-term sustainability.
In regulatory news, the FDA has approved Waskyra, a gene therapy for Wiskott-Aldrich syndrome, a rare immunodeficiency disorder. The approval marks a significant step forward for patients with limited treatment options and continues the momentum in the gene therapy space for rare diseases.
Meanwhile, OTR Therapeutics has announced a new collaboration with Zealand Pharma to co-develop treatments for metabolic diseases. The partnership combines OTR’s delivery platform with Zealand’s peptide-based therapeutic expertise, aiming to advance more effective and durable metabolic interventions.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
